Results 51 to 60 of about 11,904 (210)

EFFECTS OF 6-MONTHS TREATMENT WITH DONEPEZIL AND RIVASTIGMIN ON RESULTS OF NEUROPSYCHOLOGICAL TESTS OF MMSE, NPI, CLOCK AND BENDER IN PATIENTS WITH ALZHEIMER'S DISEASE [PDF]

Acta Medica Iranica, 2008
Alzheimer's disease is the most common degenerative disease of brain. Nowadays, the most common treatment being used to slow down disease progression, include Donepezil , Rivastigmine and Galantamine, which all of them act as inhibitors of acetyl ...
R. Abolfazli, S. Ghazanshahi M. Nazeman
doaj  

Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer’s disease in Brazil

Brazilian Journal of Psychiatry, 2018
Objective: To perform a cost-effectiveness analysis of donepezil and rivastigmine therapy for mild and moderate Alzheimer’s disease (AD) from the perspective of the Brazilian Unified Health System.
Luciana R. da Silva, Cid M.M. Vianna, Gabriela B.G. Mosegui, Antônio A.F. Peregrino, Valeska Marinho, Jerson Laks   +5 more
doaj   +1 more source

Intranasal Cerium Oxide Nanoparticles Ameliorate Cognitive Function in Rats with Alzheimer’s via Anti-Oxidative Pathway

Pharmaceutics, 2022
Cerium oxide nanoparticles (CNPs), owing to their antioxidant property, have recently emerged as therapeutic candidate for Alzheimer’s disease (AD). However, intravenous CNPs are limited due to their poor physicochemical properties, rapid blood clearance
Syed Mohammad Danish, Anshul Gupta, Urooj Ahmad Khan, Nazeer Hasan, Farhan Jalees Ahmad, Musarrat Husain Warsi, Ahmed M. Abdelhaleem Ali, Ameeduzzafar Zafar, Gaurav Kumar Jain   +8 more
doaj   +1 more source

Multi‐Targeting Ligands as Prospective Therapeutics for Alzheimer's Disease, a Prevalent Neurodegenerative Disorder: Mechanistic Insights, Emerging Targets and Drug Discovery Campaigns

Medicinal Research Reviews, Volume 46, Issue 4, Page 1173-1229, July 2026.
ABSTRACT Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by progressive cognitive impairment, memory deterioration, and neuronal dysfunction. Its complex pathophysiology involves multiple interlinked processes, including amyloid‐β (Aβ) aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation ...
Amandeep Thakur, Mandeep Rana, Sakshi Vanjani, Kei‐Chi Liou, Rajeev Taliyan, Kunal Nepali, Chih‐Hao Yang   +6 more
wiley   +1 more source

Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension

, 2020
Objective: The purpose of this study was to evaluate if the cognitive benefit of rivastigmine is affected by the presence of orthostatic hypotension (OH) in patients with Parkinson's disease dementia (PDD).
Sturchio A., Pathan R., Mahajan A., Pilotto A., Marsili L., Elango D. S., Pezous N., Espay A. J., Masellis M., Gomez-Mancilla B.   +9 more
core   +2 more sources

Synthesis and Evaluation of Novel Cinnamic Acid Hybrids With Antiacetylcholinesterase, Antioxidant, and Anti‐Inflammatory Properties

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
In this work, we identified two novel pleiotropic sinapic acid derivatives with excellent anti‐acetylcholinesterase, antioxidant, and anti‐inflammatory properties. Alzheimer's disease, one of the most widespread neurodegenerative disorders, is known for its multifactorial nature that makes it challenging to treat.
Konstantina Sdougkou, Eleni Rekka, Dionysia Papagiannopoulou   +2 more
wiley   +1 more source

Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in AppNL‐G‐F KI mice

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Whether cholinergic activity in the septohippocampal network affects cognitive dysfunction via hippocampal cholinergic neurostimulating peptide (HCNP) in Alzheimer's pathogenesis remains unclear. METHODS An Alzheimer's pathogenesis by mutation in amyloid‐beta precursor protein gene (AppNL‐G‐F) knock‐in (KI) and HCNP precursor ...
Yo Tsuda, Yuta Madokoro, Kengo Suzuki, Takuya Ooba, Toyohiro Sato, Yuto Uchida, Itsumi Nagai‐Arakawa, Takashi Saito, Hideaki Hara, Hideki Hida, Noriyuki Matsukawa   +10 more
wiley   +1 more source

Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study

, 2007
Acetylcholinesterase inhibitors (AChEIs) are effective in the treatment of cognitive symptoms in Alzheimer's disease (AD). Because the behavioral and psychological symptoms of dementia (BPSD) have also been attributed to central cholinergic deficits, we ...
Tracik, Ferenc, Kunz, Dieter, Walther, Sebastian, Eichmann, Uta, Mahlberg, Richard   +4 more
core   +1 more source

Cortical synchrony is reduced in Alzheimer's disease and relates to arousal state

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION The brain is a complex dynamical system, influenced by arousal state. Cortical synchrony supports information processing and is disrupted in Alzheimer's disease (AD). Locus coeruleus (LC) integrity and pupillometry index arousal system structure and function.
Michael C. B. David, Emma‐Jane Mallas, Magdalena A. Kolanko, Martina Del Giovane, Danielle L. Kurtin, Ramin Nilforooshan, Karl A. Zimmerman, Cristina Bonet Olivares, Peter J. Lally, CR&T Group of UKDRI, David J. Sharp, Paresh A. Malhotra, Gregory Scott   +12 more
wiley   +1 more source

Evaluation of donepezil and rivastigmine administration on the cognitive deficits induced by electroconvulsive therapy: A randomized, double-blind clinical trial

, 2019
Background. Although several medical interventions have been used to reduce the cognitive side effects of electroconvulsive therapy (ECT), no specific drug has been yet identified to solve this problem. Objectives.
Nazarinasab, Masoumeh, Mahnoo, Mahnoosh, Masoumeh Nazarinasab, Mahnoosh Hajatzadeh, Forouzan Behrouzian, Behrouzian, Forouzan   +5 more
core   +1 more source